Our work positions HHLA2 as a potential therapeutic target and, crucially, a potential non-invasive prognostic biomarker for predicting c-Met inhibitor efficacy in HCC, paving the way for precision therapy in HCC. The gene discussed is MET; the disease is hepatocellular carcinoma.